Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation.
Long-term macrolide therapy has been proven to improve survival in patients with diffuse panbronchiolitis. Although its mechanisms remain unknown, previous studies have suggested the effects of macrolide might be anti-inflammatory rather than antibacterial. To elucidate the molecular mechanisms of its action, we studied here the effects of erythromycin (EM) and its new derivative, EM703, which shows no antibacterial action, on the activation of the transcription factor nuclear factor-kappaB (NF-kappaB) in human bronchial epithelial cells. Western blotting analysis showed that EM did not inhibit the degradation of IkappaBalpha, suggesting the molecular target for EM was not the dissociation of NF-kappaB from IkappaB. An electrophoretic mobility shift assay showed that EM did not interrupt the NF-kappaB DNA-binding activity in the nucleus under the conditions tested. Moreover, not only EM but also EM703 suppressed the activation of NF-kappaB and the production of interleukin-8, demonstrating that the anti-inflammatory action of the macrolide is independent of its antibacterial activity. Taken together, these data suggest EM has an anti-inflammatory action, presumably via an interaction with the NF-kappaB signaling pathway in the downstream of the dissociation from IkappaB, resulting in the inhibition of NF-kappaB.
Desaki
Masashi
M
Department of Respiratory Medicine, University of Tokyo Graduate School of Medicine. Kitasato Medical Institute, Tokyo, Japan. desaki-tky@umin.ac.jp
Okazaki
Hitoshi
H
Sunazuka
Toshiaki
T
Omura
Satoshi
S
Yamamoto
Kazuhiko
K
Takizawa
Hajime
H
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents; D015153:Blotting, Western; D001988:Bronchiolitis / Q000188:drug therapy* / Q000473:pathology; D002478:Cells, Cultured; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis; D004247:DNA / Q000378:metabolism; D024202:Electrophoretic Mobility Shift Assay; D004847:Epithelial Cells / Q000187:drug effects; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis; D016328:NF-kappa B / Q000502:physiology*; D010766:Phosphorylation; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology*; D018808:Transcription Factor AP-1 / Q000187:drug effects / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D016209:Interleukin-8; D016328:NF-kappa B; D018808:Transcription Factor AP-1; D014409:Tumor Necrosis Factor-alpha; D004917:Erythromycin; D004247:DNA